CANF vs CDT

Can-Fite Biopharma Ltd vs CDT Equity Inc. — Valuation Comparison 2026

CANF

Pharmaceutical Preparations
Can-Fite Biopharma Ltd
Quality
2.2
out of 10
Value Trap
6
SAFE
Price
$3.35
Last close
Models
9/13
Active
VS

CDT

Pharmaceutical Preparations
CDT Equity Inc.
Quality
4.1
out of 10
Value Trap
27
LOW
Price
$1.04
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType CANF Fair ValueCANF Upside CDT Fair ValueCDT Upside
Bayesian DCF Intrinsic $0.87 -73.9% $0.62 -40.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.14 -36.2% $1.08 +3.9%
PWERM Option-Based $2.83 -15.6% $1.96 +88.4%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CANF vs CDT — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CANF vs CDT — Which Stock Is More Undervalued?

CDT scores higher with a 4.1/10 quality rating vs CANF's 2.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Can-Fite Biopharma Ltd (CANF) and CDT Equity Inc. (CDT) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CANF currently trades at $3.35 with a QOC of 2.2/10, while CDT trades at $1.04 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).